|
|
Volumn 372, Issue 15, 2015, Pages 1472-1473
|
|
The authors reply
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BRACHYTHERAPY;
CANCER CHEMOTHERAPY;
CANCER PALLIATIVE THERAPY;
CHEMORADIOTHERAPY;
CLINICAL EFFECTIVENESS;
DISEASE ASSOCIATION;
DYSPHAGIA;
ESOPHAGEAL SQUAMOUS CELL CARCINOMA;
ESOPHAGUS RESECTION;
HUMAN;
LETTER;
LUNG DISEASE;
MINIMALLY INVASIVE SURGERY;
PRIORITY JOURNAL;
RANDOMIZED CONTROLLED TRIAL (TOPIC);
RISK BENEFIT ANALYSIS;
TREATMENT RESPONSE;
WART VIRUS;
ADENOCARCINOMA;
ESOPHAGUS;
ESOPHAGUS TUMOR;
PATHOLOGY;
SQUAMOUS CELL CARCINOMA;
ADENOCARCINOMA;
CARCINOMA, SQUAMOUS CELL;
ESOPHAGEAL NEOPLASMS;
ESOPHAGUS;
HUMANS;
|
|
EID: 84927124585
PISSN: 00284793
EISSN: 15334406
Source Type: Journal
DOI: 10.1056/NEJMc1500692 Document Type: Letter |
|
Times cited : (61)
|
|
References (4)
|
